Phase II Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Cilengitide (Primary) ; Procarbazine; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms ExCentric
- 01 May 2016 Status changed from active, no longer recruiting to completed, according to results published in the Journal of Neuro-Oncology.
- 17 Feb 2015 Planned primary completion date changed to 1 Nov 2012.
- 30 May 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History